NEW YORK, Jan 4 – Third Wave Technologies said Thursday it had licensed its Invader genotyping system to Fairview University Medical Center in Minneapolis for a genotyping study to be sponsored by the NIH.
Terms of the deal were not disclosed, although Third Wave generally opts for deals that give the company rights to discoveries made using its technology.
The study will involve genotyping at least 100,000 patient samples in order to determine a connection between genetic mutations and hemochromatosis, a disease that results in abnormal iron metabolism and can cause diabetes, cardiac problems, and arthritis.
This is the largest genotyping study ever sponsored by the NIH, Third Wave and Fariview University Medical Center said in a statement.
Third Wave of Madison, Wis., is expected to announce further deals in the near future. The company has also filed to go public.